Xeris Biopharma Holdings, Inc. (XERS) stock
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Earnings
Xeris Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Xeris Biopharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 1, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $107.20M | +44.1% | $0.06 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $92.10M | +28.8% | -$0.18 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $83.13M | +38.3% | $0.01 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 2, 2026before the open | $85.81M | +42.8% | $0.06 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $74.38M | +37.0% | $0.00 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $71.50M | +48.6% | -$0.01 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $60.12M | +48.1% | -$0.06 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 6, 2025before the open | $60.10M | +35.4% | -$0.03 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024before the open | $54.30M | +12.4% | -$0.11 | -$0.06 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $48.10M | +26.6% | -$0.10 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $40.60M | +22.3% | -$0.14 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 6, 2024before the open | $44.39M | +33.9% | -$0.10 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $48.30M | +62.5% | -$0.09 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $38.00M | +50.2% | -$0.14 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $33.20M | +50.4% | -$0.12 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023before the open | $33.14M | +54.7% | -$0.10 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022before the open | $29.73M | +170.2% | -$0.16 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022before the open | $25.31M | – | -$0.19 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022before the open | $22.07M | – | -$0.25 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022before the open | $21.43M | – | -$0.42 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $11.00M | – | -$0.39 | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Xeris Biopharma's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total revenue | FY2026 | $395.00M – $405.00M | $375.00M – $390.00M | Raised | Nov 5, 2026 |
| total revenue | FY2026 | $385.00M – $390.00M | $380.00M – $390.00M | Raised | Aug 6, 2026 |
Guidance vs results
The last range Xeris Biopharma gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $285.00M – $290.00M | $291.81MΣ4Q | Above range |
Guidance history
Every forecast Xeris Biopharma put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | total revenue | FY2026 | $395.00M – $405.00M | Raised |
| Aug 6, 2026 | total revenue | FY2026 | $385.00M – $390.00M | Raised |
| May 7, 2026 | total revenue | FY2026 | $380.00M – $390.00M | New |
| Mar 2, 2026 | Total revenue | FY2026 | $375.00M – $390.00M | New |
| Nov 6, 2025 | total revenue guidance | FY2025 | $285.00M – $290.00M | New |
| Aug 7, 2025 | total revenue guidance | FY2025 | $280.00M – $290.00M | Raised |
| May 8, 2025 | total revenue guidance | FY2025 | $260.00M – $275.00M | Raised |
| Mar 6, 2025 | total revenue | FY2025 | $255.00M – $275.00M | New |
| Jan 10, 2025 | total revenue | FY2024 | $203.00M | Raised |
| Nov 8, 2024 | year-end cash | FY2024 | $68.00M – $72.00M | Narrowed |
| Nov 8, 2024 | total net revenue | FY2024 | $198.00M – $202.00M | Raised |
| Aug 8, 2024 | year-end cash balance | FY2024 | $60.00M – $75.00M | Raised |
| Aug 8, 2024 | total net revenue | FY2024 | $190.00M – $200.00M | Raised |
| May 9, 2024 | total revenue | FY2024 | $175.00M – $200.00M | Raised |
| Mar 6, 2024 | year-end cash, cash equivalents, and short-term investments | FY2024 | $55.00M – $75.00M | New |
| Mar 6, 2024 | total net revenue | FY2024 | $170.00M – $200.00M | New |
| Nov 9, 2023 | revenue guidance | FY2023 | $160.00M – $165.00M | Raised |
| Aug 8, 2023 | 2023 year-end cash balance | FY2023 | $55.00M – $65.00M | Lowered |
| Aug 8, 2023 | cash utilization | FY2023 | $57.00M – $67.00M | Raised |
| Aug 8, 2023 | total net revenue | FY2023 | $145.00M – $165.00M | Raised |
| May 9, 2023 | year-end cash, cash equivalents, and short-term investments | FY2023 | $45.00M – $65.00M | Lowered |
| May 9, 2023 | cash utilization from operating activities | FY2023 | $57.00M – $77.00M | Raised |
| May 9, 2023 | total revenue | FY2023 | $135.00M – $165.00M | Reaffirmed |
| Mar 8, 2023 | Year-end cash, cash equivalents, and short-term investments | FY2023 | $45.00M – $65.00M | Lowered |
| Mar 8, 2023 | Cash utilization from operating activities | FY2023 | $57.00M – $77.00M | New |
| Mar 8, 2023 | Combined total revenue for Gvoke, Keveyis, Recorlev, and Other 1 Revenue | FY2023 | $135.00M – $165.00M | New |
| Nov 9, 2022 | synergies | FY2022 | $50.00M | Lowered |
| Nov 9, 2022 | year-end cash balance | FY2022 | $110.00M – $120.00M | Raised |
| Nov 9, 2022 | total net product revenue | FY2022 | $105.00M – $110.00M | Lowered |
| Aug 10, 2022 | synergies | FY2022 | $50.00M | Lowered |
| Aug 10, 2022 | year-end cash balance | FY2022 | $90.00M – $110.00M | Raised |
| Aug 10, 2022 | total net product revenue | FY2022 | $105.00M – $120.00M | Reaffirmed |
| May 11, 2022 | year-end cash balance | FY2022 | $90.00M – $110.00M | Raised |
| May 11, 2022 | synergies | FY2022 | $50.00M | Lowered |
| May 11, 2022 | combined net product revenues | FY2022 | $105.00M – $120.00M | Reaffirmed |
| Mar 10, 2022 | cash, cash equivalents, and short-term investments | FY2022 | $90.00M – $110.00M | New |
| Mar 10, 2022 | Net product revenue | FY2022 | $105.00M – $120.00M | New |
| Nov 10, 2021 | net sales | FY2021 | $76.00M – $80.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Xeris Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
- News
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Update
See a number that looks wrong?